Gastrointestinal dysfunction in idiopathic Parkinsonism: A narrative review

Mehri Salari1,2, Emad Fayyazi2, Omid Mirmosayyeb2,3

1Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, 2Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, 3Medical Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Currently, gastrointestinal (GI) dysfunctions in Parkinson’s disease (PD) are well-recognized problems and are known to be the initial symptoms in the pathological process that eventually results in PD. Many types of PD-associated GI dysfunctions have been identified, including weight loss, nausea, hypersalivation, dysphagia, dyspepsia, abdominal pain, intestinal pseudo-obstruction, constipation, defecatory dysfunction, and small intestinal bacterial overgrowth. These symptoms can influence on other PD symptoms and are the second most significant predictor of the quality of life of these patients. Recognition of GI symptoms requires vigilance on the part of clinicians. Health-care providers should routinely ask direct questions about GI symptoms during office visits so that efforts can be directed at appropriate management of these distressing manifestations. Multiple system atrophy (MSA) and progressive supranuclear palsy are two forms of neurodegenerative Parkinsonism. Symptoms of autonomic dysfunctions such as GI dysfunction are common in patients with parkinsonian disorders. Despite recent progress in the recognition of GI dysfunctions, there are few reviews on the management of GI dysfunction and GI symptoms in idiopathic Parkinsonism. In this review, the clinical presentation, pathophysiology, and treatment of each GI symptom in PD, MSA, and prostate-specific antigen will be discussed.

Key words: Multiple system atrophy, Parkinson’s disease, progressive supranuclear palsy

INTRODUCTION

In addition to the cardinal motor features of the disorder, Parkinson’s disease (PD) patients suffer from a range of nonmotor symptoms, of which gastrointestinal (GI) symptoms are among the most common. GI motility is commonly disturbed in PD, manifesting as some GI symptoms. All these symptoms may precede the clinical diagnosis of PD for years.1 The most common GI symptoms in PD are weight loss, sialorrhea, dysphagia, nausea, constipation, and defecatory dysfunction, all of which reflect dysregulation of GI motility at all levels of the GI tract. Recent studies have highlighted that there is an association with disease severity and motor status and the impact on patients’ health-related quality of life (HRQL).2 Furthermore, GI symptoms have been associated with severe and potentially life-threatening complications, including malnutrition, pulmonary aspiration, megacolon, intestinal obstruction, and even perforation. Finally, they can impact on other PD symptoms. For example, slow gastric emptying decreasing levodopa bioavailability contributes to motor fluctuations in PD. Recognition of GI symptoms requires vigilance on the part of clinicians. There is a paucity of clinical trial data to guide the treatment of GI dysfunction in PD. Some recent trials have provided evidences for symptomatic treatment of hypersalivation, constipation, dysphagia, nausea, and also defecatory dysfunction.3 Multiple system atrophy (MSA) is defined as an adult-onset, sporadic, rapidly progressive, multisystem, neurodegenerative fatal disease of undetermined etiology, characterized clinically by varying severity of parkinsonian features; cerebellar, autonomic, and urogenital dysfunction and corticospinal disorders.4 It is one of the neurodegenerative forms of Parkinsonism. In the
major group with primary chronic autonomic failure, MSA (often with the Shy–Drager syndrome), GI abnormalities are often observed from the earliest stages and can result in considerable morbidity as the disease progresses.\[9\] Progressive supranuclear palsy (PSP) is one of the most forms of neurodegenerative Parkinsonism after PD, which can affect around 4.9/10,000 inhabitants.\[10\] The brainstem is one among the first regions affected in PSP and it is part of the sleep/circadian regulation network.\[7\] Symptoms of autonomic dysfunctions such as GI dysfunction are common in patients with parkinsonian disorders such as PSP. The most frequent symptom was constipation, followed by salivation and anismus, but patients with PSP most commonly complained dysphagia. The common GI dysfunction and GI symptoms in PD, MSA, and prostate-specific antigen (PSA) will be discussed in this review article.

METHODS

In this narrative review, all studies assessed GI dysfunction and GI symptoms in PD, MSA, and PSA patients. Medline, PubMed, Web of Sciences, EMBASE, and Cochrane databases up to April 2016 were included in our searches. In addition, reference lists from articles identified by search as well as a key review article to identify additional articles were included.

PARKINSON’S DISEASE

Gastrointestinal symptoms in Parkinson’s disease

Weight loss

Weight loss in PD is common and seems to correlate with worsened HRQL. Consciousness of factors related to weight loss and its relation to HRQL may help practitioners improve patient management.\[8\] A lower plasma leptin concentration and a higher serum IGF-1 concentration were found in PD patients with weight loss. Body mass index (BMI) and the source of adipose tissue were positively associated with leptin concentration in all PD patients. Paradoxically, the lesser the BMI was, the lower plasma active ghrelin concentration was in PD patients with the weight loss. Hence, leptin and ghrelin concentration can show weight loss in patients with PD.\[9\] Beyer et al. in their study showed that PD patients to be four times more likely to experience a weight loss of >10 lb since their diagnosis compared to matched controls over the same time period.\[10\] In another study, we have found that women suffering from PD exhibited a significant weight loss (−8.5%) and decreased calf circumference when compared with controls. A decrease (−4.3%) in total body weight was also found in men with PD but the difference did not reach the level of significance.\[11\] The amount of weight loss is not usually a large amount but can sometimes be more dramatic (exceeding 12.8 kg).\[12\] The reason for this unwanted weight loss is not known. Possible determinants of weight loss in PD include loss of appetite, impaired hand–mouth coordination, difficulty in chewing and dysphagia, nausea, intestinal hypomotility, and increased energy requirements because of muscular rigidity and involuntary movements. Noticeable weight gain has repeatedly been reported after subthalamic or pallidal deep brain stimulation (DBS). Excessive weight gain has been reported to occur in patients taking dopamine receptor agonists as a result of compulsive eating.\[13\] Because low body weight is associated with negative health effects and a poor prognosis, monitoring weight and nutritional status should be part of PD management. For PD patients experiencing dramatic or ongoing weight loss, evaluation for an alternative medical cause should be undertaken. Consultation with a registered dietician to evaluate daily energy intake and expenditure and to make dietary modifications is important to ensure adequate nutritional status and curtail weight loss.

Nausea

Nausea is a common side effect of dopaminergic medications, it also occurs in untreated PD patients because of the underlying gastroparesis.\[14\] Delayed gastric emptying (GE) in PD is probably multifactorial but it is at least partly related to Lewy pathology in the enteric nervous system (ENS) and discrete brainstem nuclei. Delayed GE occurs in both early and advanced PD but it is underdetected in routine clinical practice. Recognition of delayed GE is important because it can cause an array of upper GI symptoms.\[15\] Gastroparesis, or delayed GE, is reported in up to 100% of PD patients and produces symptoms such as early satiety, abdominal discomfort with bloating, nausea, vomiting, bodyweight loss, and even malnutrition.\[16\] GE time in patients with PD was delayed compared with control volunteers.\[17\] It was even slower in patients treated with levodopa, which has a significant relationship between levodopa pharmacokinetics and GE in PD patients, suggesting that delayed GE is a causative factor for producing delayed-on in PD. Therefore, studies of improved GE to ameliorate delayed-on in PD are warranted. If a patient with PD has gastroparesis, gastric scintigraphy is most often used to estimate GE. If the patient has mild disorder, treatment of gastroparesis in PD should begin with a conservative, nonpharmacologic approach. Patients can adopt a gastroparesis diet, which may serve to reduce symptoms and maintain proper nutrition and hydration status. When pharmacologic treatments are required, the use of metoclopramide (a central and peripheral dopamine receptor antagonist often used in the treatment of gastroparesis) is contraindicated in PD because it worsens Parkinsonism by blocking central dopamine receptors. Domperidone is a peripheral dopamine receptor blocker that does not cross the blood–brain barrier and...
Hypersalivation

Hypersalivation, sialorrhea, or drooling is a common symptom of PD that can significantly impair a patient’s health and quality of life. Hypersalivation can lead to aspiration and subsequent pneumonia. Recent studies have shown that saliva production is not increased in PD but it is actually diminished. In PD patients, sialorrhea is produced by saliva retention. Nevertheless, sialorrhea can produce discomfort in swallowing although without a formal complaint of dysphagia. For treating mild symptoms, some experts revealed using chewing gum or hard candy to encourage swallowing and reduce drooling in social situations. When more aggressive intervention is warranted, pharmacologic therapy to reduce saliva production is another option. Sialorrhea affects approximately 75% of patients with PD. Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness. Glycopyrrolate (glycopyronium bromide) is an anticholinergic drug with a quaternary ammonium structure not capable to cross the blood–brain barrier in large quantities. Therefore, glycopyrrolate exhibits minimal central side effects, which may be an advantage in patients with PD, of whom a significant portion already experience cognitive deficits. Oral glycopyrrolate 1 mg three times daily is an effective and safe therapy for sialorrhea in PD. In their study, Chinnapongse et al. showed that intraglandular injection of botulinum toxin Type B was safe, tolerable, and efficacious in treating sialorrhea in PD patients. Additional studies are warranted to further confirm the drug’s robust efficacy, as well as evaluate its effect with repeated dosing. One study manifested that local anticholinergics such as ipratropium bromide spray and atropine ophthalmic drops can be used sublingually to control hypersalivation in PD while decreasing systemic side effects, but they still occur.

Dysphagia

PD is associated with several nonmotor symptoms, including dysphagia (swallowing difficulties). Dysphagia can make the consumption of solid medicines difficult, which potentially contributes to the poor adherence that is common among people with PD. However, patients may be reluctant to admit that they experience dysphagia. Survey studies have suggested that approximately 50% of PD patients report symptomatic dysphagia, yet clinical assessments using barium swallowing tests and videofluoroscopy can detect abnormalities in more than 75%–97% of cases with the risk of silent aspiration. All stages of swallowing (preoral, oral, lingual, pharyngeal, and esophageal) may be affected by PD. Another study revealed that the swallowing management was characterized by swallowing assessment for every 3 months with the indication of compensatory and rehabilitation maneuvers, aiming to maintain the oral feeding without risks. There was no associated factor with swallowing functionality in this case series. One study that investigated on manometric abnormalities of the esophagus showed that multiple abnormalities in the oropharyngeal phase have been documented, including vallecula and pyriform sinus residues, delayed swallowing reflex, and deficits in laryngeal movement, and these abnormalities can lead to pneumonia. Another study like the previous study manifested that multiple abnormalities in the esophageal phase have been identified, including incomplete upper esophageal sphincter relaxation and reduced opening, high intrabolus pressure, no more peristalsis, diffuse esophageal spasms, high-range contractions, prolonged esophageal phase, and reduced lower esophageal sphincter pressure. These esophageal abnormalities can result in both dysphagia and gastroesophageal reflux. PD patients complaining of coughing or choking during meals should undergo evaluation with a modified barium swallow study. If normal, further evaluation with videofluoroscopy should be considered to evaluate esophageal function. Treatment of dysphagia has not been approved universally. Nonpharmacological techniques such as chin-down swallowing and use of the National Dysphasia Diet Program may be useful in some patients. Optimizing dopaminergic medication can be beneficial for some patients. Expiratory muscle strength training and video-assisted swallowing therapy may be effective dysphagia treatments solely or in addition to dopaminergic therapy for PD.

Dyspepsia

The autonomic problems of PD as nonmotor features include GI and urinary dysfunction, and a variety of other problems. GI dysfunction is often seen with patients complaining of disturbances of intestinal habit with constipation, bloating, flatulence, and abdominal pain. Some studies reported a high prevalence of constipation (58%) among patients with PD. However, many of dyspeptic symptoms are also related to troubles of the gastric motility probably due to neurodegenerative processes that also involve digestive system, specific dopaminergic medication, and many other causes that are not yet fully understood. There are studies showing a prevalence of delaying of GE up to 70% of patients with PD. Considering some similarities
between Fabry disease and GI involvement in PD with autonomic disorders, we decided to manage the dyspetic troubles of patients with PD with an agent used for their prokinetic abilities, such as triemebutine. Triemebutine acts on the GI tract through an agonist effect on peripheral mu, kappa, and delta opiate receptors and by releasing GI peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin, and glucagon. Triemebutine accelerates GE, induces premature Phase III of the migrating motor complex in the intestine, and modulates the contractile activity of the colon. Another study showed that GI dysfunction is one of the most common nonmotor features of PD, and one part of this dysfunction is dyspepsia. Dyspepsia is usually defined as upper abdominal pain or retrosternal pain, discomfort, heartburn, nausea, vomiting, or other symptoms considered to arise from the upper alimentary tract.

**Abdominal pain**

GI symptoms such as abdominal pain, nausea, and bloating are frequent complaints of patients with PD. One study reported that the unusual and painful abdominal contractions in patients with PD were linked to abdominal muscle hypertrophy. The abdominal pain was severe by sitting, standing, or walking, and was characterized by a powerful pulling sensation associated with evident contractions of the rectus abdominis. When the pain decreased, the camptocormia abated. The thickness of the rectus abdominis and the relative muscle thickness ratio were greater in the patients with abdominal contractions than in the control patients with PD without abdominal contractions. Palpable, painful abdominal contractions could be associated with the presence of hypertrophy of the rectus abdominis visible on CT scan. The abdominal muscle contractions probably contribute to the development of a stooped posture. Long-term levodopa use is associated with the “end-of-dose wearing off” (EODWO) phenomenon, wherein Parkinsonian symptoms return before a patient’s next scheduled dose of levodopa. Abdominal pain may be an important wearing off symptom as an early indicator of the development of EODWO in PD patients. In this report, we present two patients on levodopa therapy for PD who developed acute abdominal pain as a symptom of EODWO. Gastroparesis can cause other vexing GI symptoms such as postprandial bloating, abdominal pain, early satiety, and weight loss, all of which have been well described in PD.

**Intestinal pseudo-obstruction**

Acute intestinal pseudo-obstruction (Ogilvie’s syndrome) is characterized by physical examination and radiologic findings indicative of mechanical obstruction but in which no physical obstructive process can be found. Many factors have been associated with this syndrome which include PD and also electrolyte imbalance, systemic infection, drugs, and occasionally, neurologic disease. Intestinal pseudo-obstruction can begin at any age and it can be a primary condition (idiopathic or inherited) or caused by another disease (secondary). Secondary intestinal pseudo-obstruction can occur as a consequence of a number of other conditions, including PD, Chagas’ disease, Hirschsprung’s disease, intestinal hypoganglionosis, collagen vascular diseases, mitochondrial disease, endocrine disorders, and the use of certain medications. Another study manifested that secondary intestinal pseudo-obstruction can be caused by anticholinergic drugs and illustrated the difficulty in treating patients with PD with them.

**Constipation**

Constipation is a frequent nonmotor feature of PD. It is the most common GI symptom of the disease and it can precede motor symptoms by as much as 20 years. Constipation can produce discomfort and affect activities of daily living, productivity, and quality of life, thus warranting early diagnosis and treatment. The proposed mechanism is slowed transit through the colon. Colon transit time has been found to be up to twice as long in PD patients than controls. PD may affect the autonomic nervous system and may cause constipation; however, few studies have explored constipation preceding the motor onset of PD and also constipation occurred as early as 20 or more years before the onset of motor symptoms which is associated with an increased risk of PD. A study of more than 6000 men without PD enrolled in the Honolulu Heart Program found that the risk of future PD increases 4-fold in men who had less than one bowel movement a day when compared with men having more than one. Subsequent autopsy studies on patients with no clinical signs of Parkinsonism or dementia prior to death confirmed that late-life constipation is associated with incidental Lewy bodies in the substantia nigra and locus coeruleus as well as decreased substantia nigra neuron density. These clinical and pathologic findings suggest that constipation may in some cases represent incipient PD. The treatment of constipation may begin with conservative, nonpharmacological methods. Patients are advised to increase fluid intake, maximize dietary fiber, increase exercise, and discontinue medications that are known to exacerbate constipation. If conservative treatments fail, pharmacological treatment can be attempted with various laxatives (either bulk-forming laxatives such as psyllium or osmotic laxatives such as milk of magnesia or polyethylene glycol). For more aggressive intervention, osmotic agents are preferred over other categories of laxatives due to their safety profile with long-term use. Polyethylene glycol and lubiprostone are the first-line compounds recommended by evidence-based medicine guidelines for the treatment of constipation due to slow colonic transit in PD.
Defecatory dysfunction

Defecatory dysfunction in patients with PD may be associated with abnormalities found during colonic inertia to the anal outlet, and clinical symptoms of difficulty with the act of defecation include excessive straining, pain, and incomplete evacuation.\(^{[48]}\) Striated anal sphincter function was studied electrophysiologically and radiologically in some patients with PD and Striated anal sphincter function was studied electrophysiologically and radiologically in some patients with PD. In the investigation of Mathers SE et al. it has been demonstrated that there was paradoxical anal sphincter muscle contraction during simulated defecation straining during simulated defecation straining resembling anismus-type pelvic outlet obstruction. Radiologic studies showed functional improvement of the defecatory mechanism following the administration of the dopamine receptor agonist apomorphine in four patients. Dysfunction of the striated anal sphincter musculature may be a significant cause of constipation in some parkinsonian patients, occurring as part of the generalized extrapyramidal motor disorder and also can produce a functional outlet obstruction.\(^{[49]}\) The functional outlet obstruction may cause both excessive straining and a sense of incomplete emptying. The obstruction may also make defecation painful. Development of the functional outlet obstruction is more frequent in PD and affects more than 60% of PD patients.\(^{[50]}\) Although anorectal function can be formally evaluated using defecography and/or anorectal manometry, these studies are not routinely used in clinical practice. Unfortunately, despite its frequency and severity, no treatments for defecatory dysfunction have been rigorously studied in the PD population. Use of routine laxatives and stool softeners is generally not effective and may actually worsen the symptoms. Improvement in defecatory dysfunction has been reported to occur after subcutaneous injection of the dopamine agonist apomorphine.\(^{[42]}\) Apomorphine can correct anorectal dysfunction in PD patients, and that these abnormalities may be a consequence of dopamine deficiency secondary to the PD process. These findings may also have therapeutic implications; however, the injections of apomorphine can be technically challenging, require ultrasound guidance, and must be repeated periodically. Biofeedback techniques have not been specifically evaluated in the PD population, although they may be helpful for some patients. More effective and practical treatments for defecatory dysfunction are desperately needed. Improvement in defecation dysfunction has been reported after subcutaneous injection of the dopamine agonist apomorphine or botulinum toxin injections into the external anal sphincter and/or puborectalis muscle.\(^{[49]}\)

Small intestinal bacterial overgrowth

Patients with PD exhibit a highly increased prevalence of small intestinal bacterial overgrowth (SIBO), which has been also associated with the severity of motor fluctuations.\(^{[51]}\) Gabrielli et al. in their study reported that the prevalence of SIBO was significantly higher in PD patients than in controls (54.17% vs. 8.33%). SIBO contributes to the pathophysiology of motor fluctuations.\(^{[52]}\) The eradication of SIBO resulted in improvement in motor fluctuations without affecting the pharmacokinetics of levodopa. Therefore, it can be postulated that impaired gut motility in PD leads to SIBO, which may in turn induce a secondary inflammatory response in the gut mucosa and impair levodopa absorption.

Pathological implications

A lot of studies of clinical human materials have shown that almost all patients with PD display Lewy pathology within their ENS.\(^{[53]}\) It has become increasingly evident over the past years that PD is a metacentric neurodegenerative disease that affects several neuronal structures outside the substantia nigra, among which is the ENS.\(^{[54]}\) Clinical studies suggest that gut disorders are common in PD, and depletion of dopamine-containing neurons in the central nervous system is a basic defect in PD.\(^{[55]}\) GI symptoms in PD include reduced salivation, dysphagia, impaired GE, constipation, and defecatory dysfunction. Constipation may precede the development of somatic motor symptoms of PD for several years.\(^{[49]}\) Neuropathological studies show early accumulation of abnormal alpha-synuclein (α-SYN) containing inclusions (Lewy neurites) in the ENS and dorsal motor nucleus of the vagus, both in PD and in incidental Lewy body disease. Colon biopsy may show accumulation of α-SYN immunoreactive Lewy neurites in the submucosal plexus of PD patients. Salivary gland involvement is prominent in PD, and α-SYN pathology can be detected both at autopsy and in minor salivary gland biopsies. Examining the GI tract by endoscopy is a simple way to evaluate α-SYN deposits; however, quantification of α-SYN deposits and subsequent determination of a positive result remain somewhat ambiguous. Several issues should be considered, including the population studied, the thickness of the tissue, the site of biopsy (ascending colon vs. transverse...
colon vs. descending colon), the number of sections, the sample number of patients, available histological techniques, and the timing of detection.\textsuperscript{[57]}

\textbf{Parkinson’s disease therapies and gastrointestinal symptoms}

Dopaminergic medications remain the mainstay of medical therapy for the motor manifestations of PD, and they may impact GI symptom manifestation both positively and negatively. First, nausea and vomiting are the common side effects of all the dopaminergic medications, which can sometimes limit their use. Dopamine agonists can be an effective and safe treatment as monotherapy in PD, however psychotic symptoms remain a significant side effect. Atypical antipsychotics may not be relied upon for the correction of these symptoms due to inconsistent results about their efficacy.\textsuperscript{[58]}

Second, dopamine stimulates rectosigmoid motility in contrast to its known inhibitory effect on upper GI motility. This appears to be mediated by specific dopamine receptors and may therefore worsen the underlying gastroparesis,\textsuperscript{[15]} thereby contributing to nausea, vomiting, and other GI symptoms.\textsuperscript{[59]} Conversely, dopaminergic medications may improve other GI symptoms.\textsuperscript{[32]}

Optimizing dopaminergic medication can be beneficial for some PD patients with dysphagia.\textsuperscript{[60]} Finally, excessive weight gain has been reported to occur in patients taking dopamine receptor agonists as a result of compulsive eating. DBS may also influence GI symptom expression. Improvements in deglutition and constipation have been reported after subthalamic nucleus DBS. Weight gain has also been observed after both bilateral and unilateral subthalamic nucleus DBS surgery.\textsuperscript{[81]} The cause of weight gain following DBS is thought to be related to the suppression of chronic tremor and/or dyskinesia, although further study is needed to clarify the underlying mechanism.

\textbf{MULITPLE SYSTEM ATROPHY}

MSA is defined as an adult-onset, sporadic, rapidly progressive, multisystem, neurodegenerative fatal disease of undetermined etiology, characterized clinically by varying severity of parkinsonian features; cerebellar, autonomic, and urogenital dysfunction and corticospinal disorders.\textsuperscript{[14]}

It is one of the forms of neurodegenerative Parkinsonism (PD, idiopathic PD IPD, MSA, dementia with Lewy body, and PSP). There are many tools for differentiating between MSA with predominant parkinsonian features and PD. These include middle cerebellar peduncle (MCP) width, apparent diffusion coefficient (ADC) value of the putamen and cerebellum, and metaiodobenzylguanidine (MIBG) myocardial scintigraphy images. MCP width and ADC value of the putamen could be superior to ADC value of the cerebellum and MIBG uptake for differentiating between MSA and PD.\textsuperscript{[62]} The neuroanatomy and neurochemistry of the GI tract are closely linked to its function, and in various forms of autonomic failure there is often derangement of such function. In the major group with primary chronic autonomic failure, MSA (often with the Shy-Drager syndrome) and GI abnormalities are often observed from the earliest stages and can result in considerable morbidity as the disease progresses.\textsuperscript{[3]} Here are some GI dysfunctions in MSA patients.

\textbf{Salivary gland dysfunction}

Hypostomia and xerostomia are uncommon in MSA, unlike other groups with chronic autonomic failure such as familial amyloidosis. In some individuals with MSA in whom cholinergic function was specifically evaluated, it was not clear whether salivary secretion was impaired. Drugs such as anticholinergics are also used in the treatment of Parkinsonism in MSA and may affect salivary secretion.\textsuperscript{[63]} Excessive drooling may be a problem in later disease stages. Anticholinergic drugs may be efficient but adverse effects are frequent, including dry mouth, cognitive impairment, constipation, blurred vision, or urinary retention.\textsuperscript{[64]}

\textbf{Swallowing impairment}

Swallowing function in the oral phase becomes gradually disturbed over the progression of MSA. As the disease progresses, difficulties with swallowing occur in the majority of individuals with MSA. In combination with laryngeal paresis, there is an increased risk of tracheal aspiration, which may lead to bronchial pneumonia and sudden death.\textsuperscript{[65]} In an analysis of some MSA patients by Smith and Bryan, it was indicated that 50% of the patients had feeding difficulties. Choking and coughing, especially in relation to liquids, may occur; in the reported series, abnormalities on testing were found in the majority despite, in some, few, or no symptoms.\textsuperscript{[64]}

\textbf{Esophageal dysmotility}

The esophagus has smooth muscle in the lower third and a mixture of smooth and striated muscle in the middle third and is, thus, affected in various autonomic disorders. Dysphagia that clinically can be attributed to esophageal dysmotility, however, is less common in MSA.\textsuperscript{[66,67]}

\textbf{Pancreatic, hepatic, and gallbladder dysfunction}

In MSA, there have been no features to suggest the impairment of pancreatic exocrine function. Pancreatic endocrine function will be referred later, especially in relation to postprandial hypotension. Liver function tests are normal in MSA unless there are additional factors causing their derangement. Gallbladder function overall appears preserved, as no clinical abnormalities have been observed.\textsuperscript{[5]}
Gastric and small intestinal motility
GI symptoms are frequent complaints in patients with MSA and may be associated with reduced GI motility due to autonomic nervous system dysfunction. However, there are few reports on GE in patients with MSA. GE was significantly delayed in patients with MSA, and the delay already appeared in the early stage of the disease. Delayed GE is one of the autonomic failures and may be a clinical marker of MSA. Symptoms relating to disturbed gastric motility in MSA are uncommon, although some patients have gastric fullness postmeal that may be troublesome. Drugs such as anticholinergic and dopaminergic agents are often used to treat motor disorder and may impair motility. GE studies, mainly using radionuclide techniques, suggest that there is an initial rapid emptying phase, followed by a later, slower phase. The impairment of vagal activity in MSA may favor predisposition to a form of the “dumping syndrome,” which is known to complicate surgical procedures performed to improve gastric drainage, especially when accompanied by a truncal vagotomy.

Colonic dysfunction
Constipation is a prominent feature in the majority of patients with MSA. It may occur at an early stage, may be severe, and may result in fecal impaction, in overflow diarrhea and in fecal incontinence. In addition to exercise, high fluid and fiber intake, laxative therapy is often necessary to relieve constipation in MSA.

Anal sphincter malfunction
Decreased number of motor cells in Onuf’s nucleus without significant consequential reinnervation or upper motor neuron involvement affects the anal sphincter in MSA. Fecal incontinence may occasionally be a presenting feature in MSA, but it is uncommon even as the disease progresses.

PROGRESSIVE SUPRANUCLEAR PALSY
PSP is one of the most forms of neurodegenerative Parkinsonism after PD, which can affect around 4.9/10,000 inhabitants. PSP is a neurodegenerative disease whose characteristics include supranuclear, initially vertical, gaze dysfunction accompanied by extrapyramidal symptoms and cognitive dysfunction. The disease usually develops after the sixth decade of life, and the diagnosis is purely clinical. The brainstem is one among the first regions affected in PSP and it is part of the sleep/circadian regulation network. Symptoms of autonomic dysfunctions and GI dysfunction are common in patients with parkinsonian disorders such as PSP. Symptoms of autonomic dysfunction are variable, including GI, cardiovascular, urogenital, and sudomotor symptoms, and also sleep and respiratory disorders. One of the GI symptoms is constipation. Another study in 2009 indicated that the most frequent symptom was constipation, followed by salivation and anismus, but patients with PSP most commonly complained dysphagia. The severity of GI symptoms, especially dysphagia, was significant in PSP patients than other parkinsonian disorders.

CONCLUSIONS
GI symptoms are extremely prevalent in idiopathic parkinsonism, occur early in the disease course, and have significant concerns for patients. Dopaminergic medications remain the mainstay of medical therapy for the motor manifestations of idiopathic parkinsonism and they may impact GI symptom manifestation both positively and negatively. More clinical trials are needed to guide clinicians in the management of these symptoms, and more research is needed to clarify the mechanisms underlying deranged gut motility in idiopathic parkinsonism, which may in turn lead to improved, disease-specific therapies.

REFERENCES
1. Jost WH. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci 2010;289:69-73.
2. Li H, Zhang M, Chen L, Zhang J, Pei Z, Hu A, et al. Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord 2010;25:2740-6.
3. Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Griefer F, et al. Reduction of gastrointestinal symptoms in Parkinson’s disease after a switch from oral therapy to rotigotine transdermal patch: A non-interventional prospective multicenter trial. Parkinsonism Relat Disord 2015;21:199-204.
4. Koga S, Dickson DW, Bieniek KF. Chronic traumatic encephalopathy pathology in multiple system atrophy. J Neuropathol Exp Neurol 2016;75:963-970.
5. Mathias CJ. Gastrointestinal dysfunction in multiple system atrophy. Semin Neurol 1996;16:251-8.

6. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 1999;354:1711-5.

7. Walsh CM, Ruoff L, Varbel J, Walker K, Grinberg LT, Boxer AL, et al. Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep Med 2016;22:50-6.

8. Akbar U, He Y, Dai Y, Hack N, Malaty I, McFarland NR, et al. Weight loss and impact on quality of life in Parkinson’s disease. PLoS One 2015;10:e0124541.

9. Fiszer U, Michalowska M, Baranowska B, Wolinska-Wittor E, Jeske W, Jethou M, et al. Leptin and ghrelin concentrations and weight loss in Parkinson’s disease. Acta Neurol Scand 2010;121:230-6.

10. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller W. Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc 1995;95:979-83.

11. Durrieu G, Llu ME, Rascol O, Senard JM, Rascol A, Montastruc JL. Parkinson’s disease and weight loss: A study with anthropometric and nutritional assessment. Clin Auton Res 1992;2:153-7.

12. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57:456-62.

13. Nierenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-9.

14. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Frequency of constipation preceding Parkinson disease: A case-control study. Mov Disord 2007;22:304-10.

15. Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson’s disease: A questionnaire-based study. Parkinsons Dis 2013;2013:742128.

16. Kataoka H, Tonomura Y, Eura N, Terasima M, Kawahara M, Ueno S. Painful abdominal contractions in patients with Parkinson disease. J Clin Neurosci 2012;19:624-7.

17. Rana AQ, Depradine J. Abdominal pain: A symptom of levodopa end of dose wearing off in Parkinson’s disease. West Indian Med J 2011;60:223-4.

18. Antonacci A, Fronzoni L, Cogliandro L, Cogliandro RF, Caputo C, De Giorgio R, et al. Chronic intestinal pseudo-obstruction. World J Gastroenterol 2008;14:2953-61.

19. Howard LM, Markus H. Pseudo-obstruction secondary to anticholinergic drugs in Parkinson’s disease. Postgrad Med J 1992;68:70-1.

20. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson’s disease. Expert Opin Pharmacother 2015;16:547-57.

21. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: Response to apomorphine. Ann Neurol 1993;33:490-3.

22. Castell JA, Johnston BT, Colcher A, Li Q, Gideon RM, Castell DO. Manometric abnormalities of the oesophagus in patients with Parkinson’s disease. Neurogastroenterol Motil 2001;13:361-4.

23. Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996;11:729-32.

24. van Hooren MR, Baijens LW, Voskuilen S, Oosterloo M, Kremer B. Treatment effects for dysphagia in Parkinson’s disease: A systematic review. Parkinsonism Relat Disord 2014;20:800-7.

25. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: Implications for Parkinson disease. Mov Disord 2008;23:1065-75.

26. Hiyama T, Yoshihara M, Matsu K, Kusunoki H, Kamada T, Ito M, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22:304-10.

27. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 1999;354:1711-5.

28. Ertekin C. Electrophysiological evaluation of oropharyngeal Dysphagia in Parkinson’s disease. J Mov Disord 2014;7:31-56.

29. Luchesi KF, Katamura S, Mourão LF. Dysphagia progression and swallowing management in Parkinson’s disease: An observational study. Braz J Otolarhinolaryngol 2015;81:24-30.

30. Potulska A, Friedman A, Królčik A, Spychala A. Swallowing disorders in Parkinson’s disease. Parkinsonism Relat Disord 2003;9:349-53.

31. Castell JA, Johnston BT, Colcher A, Li Q, Gideon RM, Castell DO. Manometric abnormalities of the oesophagus in patients with Parkinson’s disease. Neurogastroenterol Motil 2001;13:361-4.

32. Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996;11:729-32.

33. van Hooren MR, Baijens LW, Voskuilen S, Oosterloo M, Kremer B. Treatment effects for dysphagia in Parkinson’s disease: A systematic review. Parkinsonism Relat Disord 2014;20:800-7.

34. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: Implications for Parkinson disease. Mov Disord 2008;23:1065-75.

35. Hiyama T, Yoshihara M, Matsu K, Kusunoki H, Kamada T, Ito M, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007;22:304-10.

36. Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson’s disease: A questionnaire-based study. Parkinsons Dis 2013;2013:742128.

37. Kataoka H, Tonomura Y, Eura N, Terasima M, Kawahara M, Ueno S. Painful abdominal contractions in patients with Parkinson disease. J Clin Neurosci 2012;19:624-7.

38. Rana AQ, Depradine J. Abdominal pain: A symptom of levodopa end of dose wearing off in Parkinson’s disease. West Indian Med J 2011;60:223-4.

39. Antonacci A, Fronzoni L, Cogliandro L, Cogliandro RF, Caputo C, De Giorgio R, et al. Chronic intestinal pseudo-obstruction. World J Gastroenterol 2008;14:2953-61.

40. Howard LM, Markus H. Pseudo-obstruction secondary to anticholinergic drugs in Parkinson’s disease. Postgrad Med J 1992;68:70-1.

41. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson’s disease. Expert Opin Pharmacother 2015;16:547-57.

42. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: Response to apomorphine. Ann Neurol 1993;33:490-3.

43. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 2009;73:1752-8.

44. Walker HC, Lyerly M, Cutter G, Hagood J, Stover NP, Guthrie SL, et al. Weight changes associated with unilateral STN DBS and advanced PD. Parkinsonism Relat Disord 2009;15:709-11.

45. Pagano G, Tan EE, Haider JM, Bautista A, Tagliati M. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson’s disease. Parkinsonism Relat Disord 2015;21:120-5.

46. Ono WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78:1650-4.

47. Cassani E, Privitera G, Pezzoli G, Pusani C, Madico L, Iorio L, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 2011;57:117-21.
48. Kim JS, Sung HY. Gastrointestinal autonomic dysfunction in patients with Parkinson’s disease. J Mov Disord 2015;8:76-82.

49. Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: A dystonic phenomenon? J Neurol Neurosurg Psychiatry 1988;51:1503-7.

50. Bassotti G, Maggio D, Battaglia E, Giulietti O, Spinozzi F, Reboli G, et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;68:76-70.

51. Fasano A, Bove F, Gabrielli M, Ragazzoni E, Fortuna S, Tortora A, et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin Neuropharmacol 2014;37:91-5.

52. Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2011;26:889‑92.

53. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.

54. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46:559-64.

55. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: The enteric nervous system spills its guts. Neurology 2011;77:1448-52.

56. Gilad R, Giladi N, Korczyn AD, Gurevich T, Sadeh M. Quantitative anal sphincter EMG in multisystem atrophy: Is there delayed gastric emptying in patients with cerebellar symptoms (MSA-C)? Eur Arch Otorhinolaryngol 2005;262:646-50.

57. Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 1992;32:134-40.

58. Gülpinar O, Haliloglu AH, Gökce MI, Arıkan N. Instillation of hyaluronic acid via electromotive drug administration can improve the efficacy of treatment in patients with interstitial cystitis/painful bladder syndrome: A randomized prospective study. Korean J Urol 2014;55:354-9.